 | • レポートコード：MRC2303B058 • 出版社/出版日：Mordor Intelligence / 2023年3月 • レポート形態：英文、PDF、111ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥665,000 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,225,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の市場調査書では、世界のレストレスレッグス症候群市場規模が予測期間中（2022～2027年）に年平均3.7％上昇すると推測されています。本調査書では、レストレスレッグス症候群の世界市場を広く調査・分析をし、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、種類別（一次性レストレスレッグス症候群、二次性レストレスレッグス症候群）分析、治療種類別（医薬品・機器、手術）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来動向などを整理しています。また、本書には、Arbor Pharmaceuticals, LLC、UCB S.A、Sun Pharmaceutical Industries Ltd、Boehringer Ingelheim International GmbH、Relegs、Restiffic、Viatris Inc、Psychocare Health Private Limited、Glenmark Pharmaceutical、Noctrix Health, Inc.などの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界のレストレスレッグス症候群市場規模：種類別 - 一次性レストレスレッグス症候群の市場規模 - 二次性レストレスレッグス症候群の市場規模 ・世界のレストレスレッグス症候群市場規模：治療種類別 - 医薬品・機器の市場規模 - 手術の市場規模 ・世界のレストレスレッグス症候群市場規模：地域別 - 北米のレストレスレッグス症候群市場規模 アメリカのレストレスレッグス症候群市場規模 カナダのレストレスレッグス症候群市場規模 メキシコのレストレスレッグス症候群市場規模 … - ヨーロッパのレストレスレッグス症候群市場規模 ドイツのレストレスレッグス症候群市場規模 イギリスのレストレスレッグス症候群市場規模 フランスのレストレスレッグス症候群市場規模 … - アジア太平洋のレストレスレッグス症候群市場規模 中国のレストレスレッグス症候群市場規模 日本のレストレスレッグス症候群市場規模 インドのレストレスレッグス症候群市場規模 … - 南米/中東のレストレスレッグス症候群市場規模 南アフリカのレストレスレッグス症候群市場規模 ブラジルのレストレスレッグス症候群市場規模 アルゼンチンのレストレスレッグス症候群市場規模 … ・競争状況 ・市場機会・将来動向 |
The restless legs syndrome market is expected to register a CAGR of 3.7% over the forecast period, 2022-2027.
The outbreak of COVID-19 has many effects, such as travel bans, flight cancellations, supply chain disruption, stock market unpredictability, falling business assurance, growing panic among the population, and uncertainty about the future had a great impact on the life of the individual. People with restless legs syndrome showed an increase in symptom severity in the early phase of the COVID-19 pandemic in the United States in 2020. For Instance, as per the Kaiser Family Foundation report 2021, The COVID-19 pandemic has negatively affected individuals’ mental health resulting in economic recession and new barriers for people already suffering from mental illness. As per the same source, during the pandemic, about 4 in 10 adults in the United States have reported symptoms of anxiety or depression.
The rise in the prevalence of restless legs syndrome is a key factor responsible for the growth of the market. According to a study published by Frontiers Media S.A., titled ‘Restless Legs Syndrome Prevalence and Clinical Correlates Among Psychiatric Inpatients: A Multicenter Study in March 2022, the reported prevalence of restless legs syndrome varied between 3.9% and 14.3%. According to the same study, the prevalence of restless legs syndrome was high among females compared to males. According to another study published in eClinicalMedicine 2022, about 25% of people with diabetes showed signs of restless legs syndrome, and people with diabetes had an increased risk of developing restless legs syndrome as compared to people without diabetes. For Instance, According to the data published by the Centers for Disease Control and Prevention 2022, 37.3 million people in the United States have diabetes which is approximately 11.3% of the United States population.
Additionally, according to the data published by Tommy’s, a registered charity in England and Wales, in 2020, nearly 20% of pregnant women develop restless legs syndrome, most probably in the third trimester of pregnancy, caused by a change in hormones. Thus, due to the above-mentioned factors, the demand for the drugs is expected to increase, thereby driving the restless legs syndrome market over the forecast period.
Restless Legs Syndrome Market Trends
Primary Restless Legs Syndrome Segment is Expected to Hold a Major Market Share Over the Forecast Period
Primary restless leg syndrome is also known as idiopathic RLS, which means the cause is unknown. There is no single definitive test for restless leg syndrome, but the condition is usually diagnosed by looking at a variety of clinical markers such as involuntary leg movements and response to dopamine-enhancing medications. The increase in the prevalence of primary restless legs syndrome is anticipated to create the demand for primary restless legs syndrome treatment, thereby driving the segment market growth over the forecast period. For instance, as per the research study published in Annals of Thoracic Medicine 2020, primary restless legs syndrome is more prevalent than secondary restless legs syndrome.
The rising work-related stress caused due to the pressure on the nervous system is expected to be a major cause of primary restless legs syndrome. For instance, as per the Health and Safety Executive 2020-21 data, in Great Britain, the total number of cases associated with work-related stress, depression, or anxiety was around 822,000, and about 850,000 workers suffering from a new case of work-related ill health in 2020/21.
North America is Expected to Dominate the Global Restless Legs Syndrome Market
North America dominated the restless legs syndrome market due to the rising prevalence of restless legs syndrome in the region. As per the data published by the sleep foundation in 2022, restless legs syndrome affects 5 to 10% of adults and 2 to 4% of children in the United States, and it is more prevalent in women than men.
As per the American Association of Neuromuscular & Electrodiagnostic Medicine 2022, there are about 12 million people in the United States may have restless legs syndrome. Restless legs syndrome has a high prevalence in central Europe and North America, with a prevalence rate of about 5-15% as per the research study published in the Journal of Communication biology 2020. According to the research data published by Neurology and Neurosurgery 2020, it was found that 5% of the United States population and 10% of the population whose age was over 65 years have the problem of restless legs syndrome.
Restless Legs Syndrome Market Competitor Analysis
The restless legs syndrome market is fragmented and consists of several major players. Some of the companies which are currently dominating the market are Arbor Pharmaceuticals, LLC., Glenmark Pharmaceutical, UCB S.A., Sun Pharmaceutical Industries Ltd, Boehringer Ingelheim International GmbH, and Relegs, Restiffic, Viatris Inc., Psychocare Health Private Limited, and Noctrix Health, Inc.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in Prevalence of Restless Leg Syndrome
4.2.2 High Unmet Need of Treatment and Increasing Geriatric Population
4.3 Market Restraints
4.3.1 Side Effects Associated with Restless Syndrome Treatments
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Type
5.1.1 Primary Restless Legs Syndrome
5.1.2 Secondary Restless Legs Syndrome
5.2 By Treatment Type
5.2.1 Medication and Devices
5.2.1.1 Dopamine Agonists
5.2.1.2 Anti-seizure Agent
5.2.1.3 Benzodiazepines
5.2.1.4 Opioids
5.2.1.5 Others
5.2.2 Surgery
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Arbor Pharmaceuticals, LLC
6.1.2 UCB S.A
6.1.3 Sun Pharmaceutical Industries Ltd
6.1.4 Boehringer Ingelheim International GmbH
6.1.5 Relegs
6.1.6 Restiffic
6.1.7 Viatris Inc
6.1.8 Psychocare Health Private Limited
6.1.9 Glenmark Pharmaceutical
6.1.10 Noctrix Health, Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS